VRPX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRPX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Virpax Pharmaceuticals's Cash Flow for Lease Financing for the three months ended in Sep. 2024 was $0.00 Mil. Virpax Pharmaceuticals's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.
Compared with last quarter ($0.00 Mil in Jun. 2024 ), Virpax Pharmaceuticals's Cash Flow for Lease Financing remained the same in Sep. 2024 ($0.00 Mil).
The historical data trend for Virpax Pharmaceuticals's Cash Flow for Lease Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virpax Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Flow for Lease Financing | Get a 7-Day Free Trial | - | - | - | - | - |
Virpax Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Cash Flow for Lease Financing | Get a 7-Day Free Trial | - | - | - | - | - |
Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.
Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Virpax Pharmaceuticals's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Sheila Mathias | officer: Chief Scientific Officer | 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312 |
Vinay Shah | officer: Chief Financial Officer | C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025 |
Barbara Ruskin | director | C/O VIRPAX PHARMACEUTICALS, INC., 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312 |
Jerrold Sendrow | director | C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380 |
Eric Floyd | director | C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380 |
Anthony P. Mack | director, 10 percent owner, officer: Chief Executive Officer | C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380 |
Michael F Dubin | director | C/O VIRPAX PHARMACEUTICALS, 1554 PAOLI PIKE #279, WEST CHESTER PA 19380 |
Vanila Singh | director | C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
Gary S Jacob | director | |
Christopher Michael Chipman | officer: Chief Financial Officer | C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380 |
Jeffrey Gudin | director, officer: Chief Medical Officer | C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380 |
Thani Jambulingam | director | C/O VIRAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380 |
Gerald W Bruce | officer: EVP, Commercial Operations | NITROMED INC, 125 SPRING STREET, LEXINGTON MA 02421 |
Virpax Pharmaceuticals Llc | 10 percent owner | C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380 |
From GuruFocus
By Business Wire • 04-30-2024
By Business Wire • 07-24-2024
By Business Wire • 11-13-2024
By Business Wire • 07-08-2024
By Business Wire • 11-22-2024
By Business Wire • 09-27-2023
By Business Wire • 05-15-2024
By Business Wire • 07-13-2023
By Business Wire • 11-17-2023
By Business Wire • 08-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.